Imunon CMO receives 21,896-share stock bonus grant

Imunon, Inc.’s Chief Medical Officer, Douglas Vincent Faller, received a stock-based bonus rather than a cash payment.

Rhea-AI Filing Summary

Imunon, Inc.’s Chief Medical Officer, Douglas Vincent Faller, received a stock-based bonus rather than a cash payment. He was granted 21,896 shares of Imunon common stock at a reference price of $1.72 per share as part of his 2025 compensation.

The footnote explains this stock grant was given in lieu of cash for 50% of his 2025 annual cash bonus. Following the grant, Faller directly owns 21,896 Imunon common shares, and the filing shows no related option exercises, sales, or derivative positions.

Insider Trade Summary

Grant/Award: 21,896 shares

Grant/Award 1 txn

Insider Faller Douglas Vincent

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,896	$1.72	$38K

Holdings After Transaction: Common Stock — 21,896 shares (Direct)

Footnotes (1)

1. F1. Stock granted in lieu of cash for 50% of 2025 annual cash bonus

Key Figures

Shares granted: 21,896 shares Grant price: $1.72 per share Shares owned after grant: 21,896 shares +1 more

4 metrics

Shares granted 21,896 shares Common stock grant to Chief Medical Officer

Grant price $1.72 per share Reference price for stock grant on 2026-06-25

Shares owned after grant 21,896 shares Total direct holdings following the transaction

Bonus portion paid in stock 50% of 2025 annual cash bonus Stock granted in lieu of cash

Key Terms

Chief Medical Officer, grant, award, or other acquisition, annual cash bonus, Form 4

4 terms

Chief Medical Officer financial

"Imunon, Inc.’s Chief Medical Officer, Douglas Vincent Faller, received a stock-based bonus"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

grant, award, or other acquisition financial

"The transaction is classified as a grant, award, or other acquisition"

annual cash bonus financial

"Stock granted in lieu of cash for 50% of 2025 annual cash bonus"

Form 4 regulatory

"After the reported transaction, Douglas Vincent Faller holds 21,896 Imunon common shares directly reported on Form 4"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Imunon (IMNN) disclose about Chief Medical Officer Douglas Faller’s latest equity grant?

Imunon reported that Chief Medical Officer Douglas Vincent Faller received a grant of 21,896 common shares. The stock was granted as part of his 2025 compensation package, replacing half of his annual cash bonus with equity rather than being an open-market purchase.

How many Imunon (IMNN) shares does Douglas Faller hold after this Form 4 transaction?

After the reported transaction, Douglas Vincent Faller holds 21,896 Imunon common shares directly. The entire position comes from this single stock grant reported in the filing, and no additional derivative holdings or other equity positions are shown in the provided data.

Was the Imunon (IMNN) Chief Medical Officer’s Form 4 transaction a market purchase or a compensation grant?

The transaction was a compensation-related grant, not a market purchase. The filing classifies it as a “grant, award, or other acquisition,” and the footnote states it was stock granted in lieu of cash for 50% of Faller’s 2025 annual cash bonus.

At what price was the Imunon (IMNN) stock grant to Douglas Faller recorded on the Form 4?

The 21,896 Imunon common shares granted to Douglas Vincent Faller were recorded at $1.72 per share. This price is used as the reference value for the grant in the filing, typical for reporting the fair market value on the grant date.

Does the Imunon (IMNN) Form 4 show any stock sales or option exercises by Douglas Faller?

The Form 4 data shows no stock sales or option exercises by Douglas Vincent Faller. It reports a single non-derivative transaction: an acquisition of 21,896 common shares as a grant, with no derivative transactions or disposals included in the summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faller Douglas Vincent

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		A		21,896(1)	A	$1.72	21,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for 50% of 2025 annual cash bonus

	/s/ Susan Eylward, Attorney-in-Fact for Douglas Faller	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)